Health-related quality of life in long-term survivors of testicular cancer.
OBJECTIVE
A growing number of patients with testicular cancer (TC) become long-term survivors. As a consequence, quality-of-life (QOL) issues become increasingly important. The objective of this study was to investigate QOL among Danish TC survivors.


METHODS
A long-term follow-up assessment of all patients with TC treated at Aarhus University Hospital in Denmark between 1990 and 2000 was conducted. A total of 401 survivors (response rate, 66%) completed questionnaires concerning QOL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30), depression (Beck Depression Inventory-II), fatigue (Multidimensional Fatigue Inventory-20), and health-related issues such as neurotoxic symptoms and Raynaud-like phenomena. On the basis of their treatment, participants were categorized as having received surveillance, radiotherapy, or chemotherapy.


RESULTS
QOL among patients with TC was equal to that of men from the general population. Although patients who received chemotherapy reported higher levels of peripheral sensory neuropathy, ototoxicity, and Raynaud-like phenomena, treatment strategies were generally unrelated to QOL and depressive symptoms.


CONCLUSIONS
Overall, the patients in this study reported high levels of QOL. The results suggest that patients treated for TC should be informed about the anticipated good post-therapeutic QOL and the low risk of psychosocial and physical long-term effects.
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. philiprossen@dadlnet.dk
Philip Blach
PB
Rossen
Anette Fischer
AF
Pedersen
Robert
R
Zachariae
Hans
H
von der Maase
D000328:Adult; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003718:Denmark; D003863:Depression / Q000209:etiology; D005221:Fatigue / Q000209:etiology; D005500:Follow-Up Studies; D006311:Hearing Disorders / Q000209:etiology; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy / Q000009:adverse effects; D010523:Peripheral Nervous System Diseases / Q000209:etiology; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D011928:Raynaud Disease / Q000209:etiology; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D011795:Surveys and Questionnaires; D017741:Survivors / Q000523:psychology*; D013736:Testicular Neoplasms / Q000523:psychology* / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome